# Effects of Chronic Cannabidiol on Alzheimer’s Disease Brain Pathology > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabidiol-alzheimer-disease-neuroprotection-study/ > **Published:** 2026-04-07T10:05:28-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:28:25-04:00 > **Clinical Summary:** Explore cannabidiol Alzheimer disease neuroprotection in a preclinical study showing effects on brain pathology and behavioral deficits in a tauopathy mouse model. --- CED Clinical Relevance  #50Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic CbdAlzheimer’SNeuroprotectionPreclinicalTau Journal Journal of [Alzheimer’s disease](https://cedclinic.com/cannabis-alzheimer-treatment-research-2025/): JAD Study Type Clinical Study Population Human participants Why This Matters This preclinical study adds to mounting evidence that cannabidiol may have neuroprotective properties relevant to [Alzheimer’s disease](https://cedclinic.com/cannabis-alzheimer-treatment-research-2025/) pathology. Understanding CBD’s potential effects on tau protein accumulation and neuroinflammation could inform future therapeutic approaches for neurodegenerative conditions. Clinical Summary Researchers administered chronic CBD to PS19 transgenic mice, an established model of tauopathy and Alzheimer’s disease pathology. The study examined CBD’s effects on tau protein pathology, neuroinflammation, and behavioral deficits characteristic of this mouse model. Key findings suggested CBD may reduce certain markers of neurodegeneration and improve some behavioral outcomes, though the mechanisms remain incompletely understood. As with most preclinical studies, translation to human therapeutic applications requires significant additional research. Dr. Caplan’s Take “While intriguing, this mouse study doesn’t change my current clinical approach to patients with cognitive concerns. The gap between promising preclinical [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) and proven human therapeutic benefit remains substantial.” Clinical Perspective 🧠 Clinicians should view this as early-stage research that may eventually inform therapeutic development rather than current treatment guidance. Patients interested in CBD for cognitive health should understand that mouse studies, while scientifically valuable, don’t establish clinical efficacy or safety in humans with Alzheimer’s disease. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20The%20effects%20of%20chronic%20cannabidiol%20administration%20on%20brain%20pathology%20and%20behavio...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41736228/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41736228/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20The%20effects%20of%20chronic%20cannabidiol%20administration%20on%20brain%20pathology%20and%20behavio...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41736228/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41736228/](https://pubmed.ncbi.nlm.nih.gov/41736228/) Table of Contents - [FAQ](#FAQ)[What is the clinical significance of this CBD study for Alzheimer’s patients?](#What_is_the_clinical_significance_of_this_CBD_study_for_Alzheimer8217s_patients) - [How does CBD potentially help with Alzheimer’s disease pathology?](#How_does_CBD_potentially_help_with_Alzheimer8217s_disease_pathology) - [Can patients with Alzheimer’s currently use CBD based on this research?](#Can_patients_with_Alzheimer8217s_currently_use_CBD_based_on_this_research) - [What are the limitations of using mouse models for Alzheimer’s research?](#What_are_the_limitations_of_using_mouse_models_for_Alzheimer8217s_research) - [What should clinicians know about the current evidence level for CBD in neurodegenerative diseases?](#What_should_clinicians_know_about_the_current_evidence_level_for_CBD_in_neurodegenerative_diseases) - [Related](#Related) ## FAQ #### What is the clinical significance of this CBD study for Alzheimer’s patients? This study examined CBD’s effects on tau pathology in a mouse model of Alzheimer’s disease, specifically the P301s-line PS19 model. While promising for understanding neuroprotective mechanisms, this is early-stage preclinical research that requires extensive human [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) before any therapeutic recommendations can be made. #### How does CBD potentially help with Alzheimer’s disease pathology? CBD may provide neuroprotective effects by targeting tau protein pathology, one of the key hallmarks of Alzheimer’s disease alongside amyloid plaques. The study investigated whether chronic CBD administration could reduce brain pathology and behavioral deficits associated with tau accumulation. #### Can patients with Alzheimer’s currently use CBD based on this research? No, this preclinical mouse study alone does not provide sufficient evidence to recommend CBD for [Alzheimer’s treatment](https://cedclinic.com/cannabidiol-alzheimers-neuroprotection-benefits/). Patients should consult their healthcare providers and await results from human [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) before considering CBD as a therapeutic option. #### What are the limitations of using mouse models for Alzheimer’s research? Mouse models like the P301s-line PS19 provide valuable insights into disease mechanisms but may not fully replicate human Alzheimer’s pathology and drug responses. Results from animal studies often do not translate directly to humans, requiring careful validation through clinical trials. #### What should clinicians know about the current evidence level for CBD in neurodegenerative diseases? The evidence for CBD in Alzheimer’s remains at the monitored relevance level, representing early-stage research requiring further validation. Clinicians should inform patients that while preclinical studies show promise, robust human clinical data is needed before incorporating CBD into treatment protocols. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [CBD:THC Ratios Show Neuroprotection in Brain Injury Study – CED Clinic](https://cedclinic.com/cbd-thc-ratios-brain-injury-neuroprotection-clinical-analysis/) Explore how different CBD:THC ratios may offer neuroprotective benefits in brain injury, relevant to neurodegenerative research. [Read More](https://cedclinic.com/cbd-thc-ratios-brain-injury-neuroprotection-clinical-analysis/) [Can Cannabis Help Slow Alzheimer's Disease? A Recent Study Says It Might – Food & Wine](https://cedclinic.com/can-cannabis-help-slow-alzheimers-disease-a-recent-study-says-it-might-food-wine/) Review recent findings on [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) and their potential to slow Alzheimer's disease progression. [Explore Study](https://cedclinic.com/can-cannabis-help-slow-alzheimers-disease-a-recent-study-says-it-might-food-wine/) [Cannabidiol as a Prophylactic Agent Against Glioblastoma Growth: A Preclinical Investigation.](https://cedclinic.com/cbd-glioblastoma-prevention-preclinical-study-results/) Learn about cannabidiol's potential neuroprotective role in glioblastoma prevention from preclinical research. [Discover More](https://cedclinic.com/cbd-glioblastoma-prevention-preclinical-study-results/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).